Phase 1/2 Study of BLU-451 in Advanced Cancers with EGFR EXON20 Insertion Mutations

Clinical Trial Grant

Duke Scholars

Principal Investigator Thomas Eldridge Stinchcombe Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

Blueprint Medicines Corporation

Start Date

September 1, 2023

End Date

August 27, 2024

Administered By

Duke Cancer Institute

Awarded By

Blueprint Medicines Corporation

Start Date

September 1, 2023

End Date

August 27, 2024